PRMTs, like the coactivator-associated arginine methyl-transferase (CARM1) and PRMT5, have been described to play an important role in cancer as their expression increases in breast and prostate cancers, for CARM1, and lymphoma, for PRMT5. Here, PRMT5 is linked to prostate carcinoma.